Archiv
Archiv anzeigen:
bis


Chemotherapy for Colorectal Cancer Also Kills Adenomas

Douglas K. Rex, MD reviewing Lee HS et al. Gastrointest Endosc 2017 Apr 18

Adjuvant chemotherapy after curative resection reduced the incidence of advanced adenomas by 85% in patients with low-risk stage II CRC.


Better Diets Protect Against Left-Sided Colon Cancer

Douglas K. Rex, MD reviewing Park SY et al. Gastroenterology 2017 Apr 17

Risk is reduced for individuals in the highest versus lowest healthy-eating quintile.


Colonoscopy for Women with History of Breast Cancer: How Often?

Douglas K. Rex, MD reviewing Lai JH et al. Gastrointest Endosc 2017 Apr 20

A meta-analysis indicates there's no need to decrease the interval between colonoscopies or other forms of screening.


Selumetinib for KRAS-Mutated Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Jänne PA et al. JAMA 2017 May 9

The MEK inhibitor selumetinib does not appear to improve survival, contrary to prior findings.


A Promising New Option for NK/T-Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Kwong Y-L et al. Blood 2017 Apr 27, Jaccard A and Hermine O. Blood 2017

Pembrolizumab induced complete remission in five of seven heavily pretreated and relapsed patients.


Adjuvant Bevacizumab for Triple-Negative Breast Cancer

William J. Gradishar, MD reviewing Bell R et al. Ann Oncol 2017 Apr 1

Adding bevacizumab to chemotherapy failed to improve 5-year overall survival.


Intracranial Hemorrhage in Anticoagulated Glioma Patients

David Green, MD, PhD reviewing Mantia C et al. Blood 2017 May 3

Anticoagulation with enoxaparin significantly increased risk for major intracranial hemorrhage in patients with glioma.


Response to Rituximab in Immune Thrombocytopenia

David Green, MD, PhD reviewing Porcelijn L et al. Blood 2017 May 3

Low response is associated with lack of platelet autoantibodies.


What's in a (Lymphoma) Name?

Michael E. Williams, MD, ScM reviewing Laurent C et al. J Clin Oncol 2017 May 1

Expert hematopathology review and classification improved the accuracy of diagnosis and treatment planning.


Stopping Eculizumab in Patients with Atypical Hemolytic Uremic Syndrome

David Green, MD, PhD reviewing Merrill SA et al. Blood 2017 May 1

Eculizumab can be discontinued despite continued complement activation.


Archiv
Seite von 55
Editorial Member Board Empfehlungen

Prof. Dr. med. Florian Otto

Tumor- und Brustzentrum ZeTuP, St. Gallen

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Immuntherapie ist in aller Munde. Checkpoint-Inhibitoren werden bei praktisch allen onkologischen Erkrankungen erprobt und erweisen sich häufig als wirksam – zumindest für eine gewisse Zeit. Aber wie entwickelt sich eine Resistenz? Dieser Frage sind Zaretsky und Kollegen im Kontext von vier Melanompatienten unter Pembrolizumab-Therapie nachgegangen und haben Defekte im Interferon-Signalweg sowie der Antigenpräsentation in den Tumorzellen gefunden.

Kommentar weiterlesen

Management of Localized Prostate Cancer: Data at Last

Robert Dreicer, MD, MS, FACP, FASCO reviewing Hamdy FC et al. N Engl J Med 2016 Sep 14, D'Amico AV. N Engl J Med 2016 Sep 14

Mortality was similar with active monitoring, prostatectomy, or radiotherapy during 10 years of follow-up.


Hereditary Thrombophilia and Risk for Pregnancy-Associated Venous Thromboembolism

David Green, MD, PhD reviewing Gerhardt A et al. Blood 2016 Sep 9

Pregnant women with inherited thrombophilia have increased risk for VTE, independent of a family history of VTE.


Little Benefit to Extensive Breast Cancer Monitoring

William J. Gradishar, MD reviewing Accordino MK et al. J Clin Oncol 2016 Aug 20, Smith KL and Smith TJ. J Clin Oncol 2016 Aug 20

The use of >12 serum tumor marker tests and/or 4 radiographic imaging tests per year provided no survival advantage.


FOLFOX Equals or Betters Epirubicin, Cisplatin, and Fluorouracil in Esophagogastric Cancer

David H. Ilson, MD, PhD reviewing Enzinger PC et al. J Clin Oncol 2016 Aug 10

Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.


Reversing Anticoagulant-Associated Bleeding with Andexanet

David Green, MD, PhD reviewing Connolly SJ et al. N Engl J Med 2016 Aug 30

Andexanet reduced anti–factor Xa activity and restored effective hemostasis in patients with major bleeding.


Another Tool to Help Breast Cancer Patients Avoid Chemotherapy

William J. Gradishar, MD reviewing Cardoso F et al. N Engl J Med 2016 Aug 25, Hudis CA and Dickler M. N Engl J Med 2016 Aug 25

A 70-gene signature identified patients with high clinical risk and low molecular risk who achieved a 5-year survival rate of 94.7% without chemotherapy.


Daratumumab for Advanced Light Chain Amyloidosis

David Green, MD, PhD reviewing Sher T et al. Blood 2016 Aug 19

Declines in light chain levels were achieved in heavily pretreated patients.


HER2 a Potential Target in Colorectal Cancer

David H. Ilson, MD, PhD reviewing Sartore-Bianchi A et al. Lancet Oncol 2016 Jun

The HER2-targeted combination regimen of trastuzumab and lapatinib may have activity in HER2-positive, chemotherapy-refractory disease.


Resistance to Anti–PD-1 Therapy in Melanoma Patients

Jeffrey A. Sosman, MD reviewing Zaretsky JM et al. N Engl J Med 2016 Jul 13

Mutations preventing interferon-receptor signaling and antigen presentation are linked to acquired resistance.


Adjuvant S-1 for Resected Pancreatic Cancer

David H. Ilson, MD, PhD reviewing Uesaka K et al. Lancet 2016 Jun 2, Ko AH et al. Lancet 2016 Jun 2

Overall survival was significantly better with S-1 versus gemcitabine.